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Abstract 
Background & Aims: Controversy exists on the impact of non-selective beta-blockers 
(NSBBs) on survival in patients with ascites. We assessed whether NSBB treatment affects 
survival in a cohort of 316 consecutive patients with ascites undergoing evaluation for liver 
transplantation. 
Methods: Consecutive patients with cirrhosis and ascites assessed for liver transplantation 
between 2011-2014 were retrospectively evaluated. Cox regression and competing risk 
analysis were performed to identify predictors of survival.  
Results: 316 patients were evaluated: males 229 (73%), mean age 54 years, median follow-
up: 7 months. Refractory ascites was diagnosed in 124 (39%) patients. Patients receiving 
NSBBs (n=128, 40.5%) had a higher frequency of previous spontaneous bacterial peritonitis 
(27% vs. 17%, p=0.025), lower frequency of refractory ascites (32% vs. 44%, p=0.03) but 
similar MELD and UKELD scores. Overall 80 (25%) patients died: 20 (16%) in the NSBB 
group vs. 60 (32%) in the non-NSBB group (p=0.002). In multivariate competing risk Cox 
regression analysis, NSBB use was associated with reduced mortality (HR=0.55, 
95%CI=0.33-0.94) along with prophylactic antibiotic use (HR=0.33, 95%CI=0.14-0.74), 
MELD score (HR=1.10, 95%CI= 1.06-1.14) and sodium levels (HR=0.94, 95%CI 0.89-
0.98).. No impact on survival was found  when considering only patients with refractory 
ascites  (NSBB use: HR=0.43, 95%CI=0.20-1.11).  
Conclusions: Patients with ascites on NSBBs didn’t have impaired survival compared to 
those not receiving NSSBs and interestingly this observation was also confirmed in the 
subgroup with refractory ascites. Our results suggest that NSBBs are not detrimental, but 
instead seem  safe even in more advanced stages of cirrhosis in patients on a transplant 
waiting list. 
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Key points 
• Non-selective beta blockers (NSBB) are widely used in patients with cirrhosis 
for primary and secondary prevention of variceal bleeding. Controversial data 
exist on their role in advanced cirrhosis. 
• Our study showed that NSBBs do not affect survival in patients with cirrhosis 
and ascites in a transplant waiting list 
• NSBB use was not associated with impaired survival in patients with 
refractory ascites 
• A thorough evaluation should be carried out before discontinuing these drugs 
in advanced cirrhosis  
 
Introduction 
Non-selective beta-blockers (NSBBs) are currently recommended for the primary and 
secondary prophylaxis of variceal haemorrhage in cirrhotic patients 1-3. Traditionally they 
have been associated with improved survival 4-6 and reduced incidence of portal 
hypertension-related complications 7-9. However, their benefits have been recently questioned 
after a poor survival rate has been reported in patients with refractory ascites treated with 
NSBBs 10. Use of NSBBs in patients with advanced stage of cirrhosis has been associated 
with deleterious effects, such as an increased incidence of paracentesis-induced circulatory 
dysfunction, hepato-renal syndrome (HRS) and acute kidney injury 11, 12. Therefore it has 
been suggested that cirrhotic patients with portal hypertension may only benefit from NSBBs 
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use within a well-defined phase of the natural history of the disease, starting with the 
development of esophageal varices and ending with the occurrence of refractory ascites or a 
severe complication such as spontaneous bacterial peritonitis (SBP) or HRS 13. However no 
universal consensus exists on this topic, particularly as NSBBs have also been shown to 
lower the risk of SBP in patients with ascites through a possible decrease in gut permeability 
and bacterial translocation 8, 14, 15. Moreover improved transplant-free survival has been 
recently reported in cirrhotic patients with ascites awaiting liver transplantation and taking 
NSBBs 16, thus supporting the use of these drugs even in advanced stages of cirrhosis. 
Finally, no impact of NSBBs on survival was observed in a post-hoc analysis of three 
randomised control trials including cirrhotic patients with ascites 17.  
In this setting, we assessed whether NSBB treatment could affect survival in a cohort of 
patients with ascites, undergoing evaluation for potential liver transplantation in our centre.  
 
Patients and methods 
This was a single-centre retrospective audit including consecutive patients with cirrhosis and 
ascites, who were assessed for liver transplant suitability between January 2011 and October 
2014 at the Royal Free Hospital following recent concerns on their use in such patients. As 
such, ethical approval and consent was not required. The following variables at the time of 
transplant assessment were recorded: age, gender, blood group, body mass index (BMI), heart 
rate, blood pressure, aetiology of cirrhosis, presence of hepatocellular carcinoma (HCC), 
diabetes mellitus, nutritional status, previous episodes of variceal bleeding, hepatic 
encephalopathy, spontaneous bacterial peritonitis, hepato-renal syndrome, and laboratory 
data.  
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Patients were divided in two groups according to whether they were receiving NSBBs or not 
at the time of transplant assessment. The type of NSBB and the duration of treatment were 
recorded, as well as the prescription of diuretics and long-term antibiotic prophylaxis for 
spontaneous bacterial peritonitis. Presence of ascites was defined on the basis of clinical 
and/or radiological findings, and its severity was graded according to the International 
Ascites Club criteria 18.  Child-Pugh score, Model for End-Stage Liver Disease (MELD) 
score and UK Score for Patients with End-Stage Liver Disease (UKELD) were calculated as 
per published equations 19, 20 at the time of transplant assessment. Glomerular filtration rate 
was estimated (eGFR) using the modification of diet in renal disease (MDRD) study formula 
21
.  
 
Statistical analysis 
Categorical variables were expressed as counts and percentages, and compared using the Chi 
Square test. Continuous variables were reported as median and interquartile ranges IQR (or 
mean and standard deviations when appropriate) and compared with the Wilcoxon/Mann 
Whitney test or student-T test when appropriate.  
A competing risk Cox regression model was used to analyze the independent risk of two 
failure types, namely death and transplantation. Patients that stopped NSBB during the 
follow-up period were censored at the time of drug discontinuation. Variables with p≤0.10 at 
univariate analysis were entered in the multivariate model, using a stepwise forward 
approach. The results are reported as hazard ratios (HRs) with 95% confidence interval (CIs) 
and the significance was set at a 0.05 level. A simple Cox regression model is reported in the 
Supplementary material. 
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A propensity analysis using logistic regression was carried out to create a score for patients 
who were receiving NSBBs and those that were not receiving NSBBs. The model for 
Propensity Score (PS) included HCC, age, gender, MELD, sodium, prophylactic antibiotic 
use, previous variceal bleeding as well as the interaction term (prophylactic antibiotic use, 
previous variceal bleeding) with p≤0.1. We used the nearest neighbour method with no 
replacement to match NSBB patients and non-NSBB patients, with a caliper width of 0.2 of 
the standard deviation of the logit of the PS. After matching, appropriated paired tests were 
used (Wilcoxon signed-rank test for continuous variables, McNemar  test for 2×2 tables and 
McNemar-Bowker test for tables with more than two response categories). 
All analyses were performed using SPSS version 22.0 (IBM, New York, NY, USA), except 
for the competing risk analyses, which were performed using Stata version 12.1 (Statacorp, 
College Station, Texas, USA). 
 
Results 
Patient characteristics 
A total of 316 patients were evaluated with a median follow up of 7 months (±12). Clinical 
characteristics, biochemical values and treatment at inclusion are summarised in Table 1. 
Mean age was 54 years. Alcohol and viral hepatitis were the most common causes of 
cirrhosis, accounting for almost the 70% of cases. The frequency of previous variceal 
bleeding, spontaneous bacterial peritonitis and hepatic encephalopathy were 32.3%, 20.3% 
and 45.3%, respectively. Median MELD score was 15 (6-40), while median UKELD was 55 
(43-85). Only 6% of the population was classified as Child-Pugh A class and these patients 
had HCC. Refractory ascites was diagnosed in 124 (39%) patients, the majority of patients 
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with grade III ascites. Only 6 patients with severe ascites did not fulfil the criteria for 
refractory ascites. One hundred and twenty-eight patients (40.5%) received NSBB for 
prevention of variceal bleeding: 92% used propranolol (median daily dose 80 mg, IQR 40), 
while only 8% received carvedilol (median daily dose 6.25 mg). Twenty-two (6%) patients 
discontinued NSBBs during follow-up. The reasons for discontinuation were: drug 
intolerance (n=11), transjugular intrahepatic portosystemic shunt (TIPSS) (n=6), HRS (n=3) 
and SBP (n=2). Treatment with furosemide or spironolactone were documented in 114 
(36.6%) and 215 (69%) patients respectively. Use of antibiotics for SBP prophylaxis was 
recorded in 57 (19%) patients. During follow-up 26 (8%) patients underwent TIPSS 
placement for the management of ascites (8 in NSBB group and 18 in no-NSBB group). 
 
Comparison between NSBB and non-NSBB group 
The comparison between NSBB and non-NSBB group is shown in Table 1. Patients receiving 
NSBB had a higher frequency of previous variceal bleeding (NSBB 50% vs. no-NSBB 
20.7%, p<0.001) and spontaneous bacterial peritonitis (NSBB 27.4% vs. no-NSBB 16.8%, 
p=0.025).  In no-NSBB group, patients with a history previous bleeding did not receive 
NSBBs due to the presence of TIPSS (n=11) or drug intolerance (n=27). More patients had 
varices (98% vs. 58%, p<0.001), while the proportion of patients with grade III and refractory 
ascites was significantly lower in the NSBB group (46.3% and 44% vs. 36.6% and 32%  
p=0.013 and 0.03 respectively). All patients on NSBBs had varices, except from two who had 
portal hypertensive gastropathy. Of the patients with varices not on NSBBs, 53 (48%) had 
previous endoscopic band ligation, 49 (45%) had small varices and 8 (7%) had medium size 
varices. As expected, heart rate was significantly lower in NSBB group (70 vs. 81 bpm, 
p=0.001), as well as mean arterial blood pressure (MAP: 80 vs. 86 mmHg, p=0.012). Other 
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significant differences were found in platelet count (87 x109 in NSBB vs. 96 x109/l in non-
NSBB, p=0.016), white blood cell count (5.04 vs 5.8 x106/l, p=0.037), haemoglobin levels 
(11.1 vs. 10.7 g/dl, p=0.034) and sodium (137 vs. 135 mmol/L, p=0.002). MELD and 
UKELD score were similar between the two groups. There was no difference in MAP and 
GFR in patients with Child-Pugh C in the NSBBs and non-NSBBs group. Diuretics were 
more frequently prescribed in NSBB group with 47% of patients receiving furosemide and 
82% spironolactone, compared to 29% and 60% in non-NSBB group. This was due to the 
fact that more patients with refractory ascites who were not on diuretics were included in the 
non-NSBB group. The median daily dose of diuretics did not differ between the two groups. 
 
Outcome in whole population 
Overall 80 (25.3%) patients died after a median follow up of 4 months (range 0-37) or 125 
days (5-1123): 20 (16%) in NSBB group vs. 60 (32%) in no-NSBB group (p=0.002). Causes 
of death were: liver failure (n=28, 35%), infection (n=16, 20%), haemorrhage (n=7, 9%), 
non-liver related (n=5, 6%), multiple-organ failure (n=4, 5%) and hepatocellular carcinoma 
(n=3, 4%). The exact cause was not reported in 17 (21%) cases. No difference was found 
between NSBB and no-NSBB patients regarding the cause of death.   
Two hundred and sixteen (68%) patients were listed for liver transplantation: 98 (76%) 
among NSBB patients compared to 118 (63%) among no-NSBB patients, p=0.01). Of them, 
146 (46.2%) were transplanted (62 (48%) in NSBB group versus 84 (45%) in no-NSBB 
group, p=NS) after a median time of 150 days (8-920).  
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Twenty-six (8.6%) patients developed SBP, while 22 (7.3%) experienced an episode of 
hepatorenal syndrome without significant difference between NSBB and non-NSBB group. 
Variceal bleeding occurred in 22 patients (7.3%) with similar prevalence between NSBB and 
non-NSBB group (10 (8%) in NSBB versus 12 (7%) in no-NSBB group, p=0.723).  
 
Predictors of mortality in the whole population 
Variables associated with mortality in the univariate and multivariate competing risk Cox 
regression analyses are shown in Table 2. In the multivariate analysis use of NSBB was 
associated with reduced mortality  (HR=0.55, 95% CI=0.33-0.94 p=0.03). Other factors 
significantly associated with mortality were prophylactic antibiotic use (HR=0.33, 95% 
CI=0.14-0.74, p=0.007) MELD score (HR=1.1, 95% CI=1.06-1.14, p<0.001) and sodium 
(HR= 0.94, 95% CI= 0.89-0.98, p=0.004).  
In the multivariate Cox regression analysis on propensity-risk score matched patients no 
association between NSBBs and mortality was found (Table 3). The only factors associated 
with mortality were severe malnutrition at the time of liver transplant work-up (HR=2.84, 
95% CI= 1.45-5.54, p=0.002), MELD score (HR=1.08, 95% CI= 1.04-1.12, p<0.001) and 
sodium (HR=0.92, 95% CI= 0.86-0.99, p=0.021). Characteristics of propensity-risk score 
matched patients are shown in Supplementary Table 1. 
In standard multivariate Cox-regression analysis, NSBB use was again associated with 
reduced mortality (HR=0.56, 95%CI=0.33-0.96, p=0.036, Supplementary Table 2 and 
Supplementary Figure 1). No significant difference was observed in all analyses when we 
excluded patients who had TIPSS (data not shown). 
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Outcomes and predictors of mortality in patients with refractory ascites.  
Refractory ascites was diagnosed in 124 (39%) patients (Supplementary Table 3). Patients 
taking NSBB (41, 33%) had more frequently a history of variceal bleeding (61% vs. 19.3%, 
p<0.001) and spontaneous bacterial peritonitis (44% vs. 25%, p=0.033). Mean systolic and 
diastolic arterial pressures were lower in NSBB group (82 vs. 83 mmHg, p=0.012 and 65 vs. 
68 mmHg, p=0.014, respectively), as well as white blood cell count (5.4 vs. 6.8, p=0.024). 
Serum sodium levels were significantly higher in patients taking NSBBs (137 vs. 133 
mmol/l, p=0.004).  
Overall forty-nine (39%) patients underwent liver transplantation after a median time of 4 
(±7) months, while 34 (27%) died after a median follow-up of 2.5 (±4) months. Of them, 6 
(17.6%) were in NSBB group and 28 (82.4%) in non-NSBB group (p=0.005). Causes of 
death were liver failure (50%), infections (23.5%), haemorrhage (11.8%), multi-organ failure 
(3%), non-liver related (3%) and unknown (8.8%). There was no difference in the cause of 
death between the two groups.  
Variables associated with mortality on competing risk Cox regression analysis are shown in 
Table 4. No association was found between NSBB use and mortality in multivariate analysis 
(HR=0.47, 95%CI=0.2-1.11, p=0.086). When propensity-score matched patients were 
analysed, NSBBs was associated with reduced mortality (HR=0.09, 95%CI=0.01-0.54, 
p=0.009) (Table 5). Characteristics of propensity-risk score matched patients are shown in 
Supplementary Table 4. Similar results were obtained from Cox regression analysis. 
(HR=0.285, 95% CI=0.11-0.70, p=0.006) (Supplementary Table 5 and Supplementary Figure 
2). 
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Influence of NSBBs on SBP incidence. 
NSBB group had a lower frequency of SBP (5.6% vs. 10.9%), however this difference did 
not reach statistical significance (p=0.106). Kaplan Meier analysis showed a trend toward a 
protective effect of NSBBs against SBP, although it was not statistically significant (log rank 
test p=0.128). The same results were found when considering only patients with refractory 
ascites (data not shown). 
 
Discussion 
In this large single-centre retrospective study, we assessed whether NSBB use could affect 
survival in patients with cirrhosis and ascites undergoing evaluation for potential liver 
transplantation. In our cohort, NSBB use was not associated with impaired survival in 
patients with ascites or refractory ascites and appeared safe even in more advanced stages of 
cirrhosis. Although our data suggest improved survival in patients with ascites on NSBBs, 
causality cannot be established from observational studies and this will need further 
confirmation in prospective studies. None of the analyses showed a detrimental effect of 
NSBBs on survival. 
Our findings conflict with those by Serstè et al. who were the first to question the beneficial 
role of NSBBs in advanced cirrhosis, showing an increased mortality among patients with 
refractory ascites treated with these drugs 10, 11. The authors concluded that NSBBs should be 
contraindicated in this population, triggering a lively debate within the hepatology 
community on whether NSBBs should be stopped or not in end-stage cirrhosis. Close 
monitoring is currently recommended for patients with end-stage liver disease receiving 
NSBBs and dosage reduction or drug discontinuation may be considered in the presence of 
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low blood pressure and renal impairment 1. However no universal consensus exists on this 
topic since opposite results supporting the beneficial role of NSBBs have recently been 
reported. Leithead et al. showed that patients receiving NSBBs while on LT waiting list had a 
reduced transplant-free mortality compared to those not on beta blockers 16. Similarly, 
Mandorfer et al 12 observed a 25%-reduction in mortality risk for patients with cirrhosis and 
ascites treated with NSBBs, while an impaired survival was only found after the development 
of SBP. This observation reinforced the so-called “window hypothesis”, which considers the 
beneficial effect of beta blockers as limited to a specific period of the natural history of 
cirrhotic disease 13. Finally, a recent study conducted on cirrhotic patients developing acute-
on-chronic liver failure, reported an improved 28-day survival in patients taking NSBBs, 
further supporting the benefit of these drugs even in the acutely ill  cirrhotic population 22 .  
The reason for such a controversial results might be related to the different characteristics of 
the studied populations concerning the disease severity and beta-blockers dosage. In our 
cohort, the two groups were well-matched with regards to possible confounding factors that 
could affect survival, such as the presence of hepatocellular carcinoma, hepatic 
encephalopathy and malnutrition. As expected, patients taking NSBBs had a higher 
frequency of varices and previous variceal bleeding, while refractory ascites was more 
common in the non-NSBB group. However no significant difference was observed in the 
markers of hepatic synthetic function, as documented by the similar MELD score (14 in 
NSBB and 15 in non-NSBB group). When compared to the population studied by Serstè et al 
10
, our patients were younger and with a more compensated liver disease. In fact, we had a 
lower proportion of Child-Pugh C patients (49% vs. 67.5%), HCC (8% vs. 27%) and lower 
MELD score (15 vs. 18.8). Moreover, renal dysfunction, defined as a serum creatinine level 
greater than 1.5mg/dl, was documented at entry only in 16% of patients compared to a third 
of French patients. By contrast, the overall frequency of varices was higher than in Serstè et 
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al. cohort (80% vs. 49%) and less different between NSBB and non NSBB group (94% and 
69% vs. 100% and 4% in NSSB and non-NSBB group, respectively). Finally, in our 
population propranolol was administered at a lower daily dose with only 8% of patients 
taking 160 mg compared to 46.7% in the French cohort. This is also in line with previous 
studies by Leithead et al, whose median propranolol dose was 80 mg/day 16, and Mandorfer 
et al, where only 5% of patients received a higher dose of 100-120 mg/day 12. We must 
therefore acknowledge that all these factors could have contributed to the lower mortality rate 
observed in our study and therefore counterbalanced in some way the potential negative 
effect of NSBBs use. However it should be noted that patients taking NSBBs did not have 
impaired survival despite having a significantly lower heart rate and mean arterial blood 
pressure, which are considered poor prognostic markers in cirrhotic patients with ascites23.  
No difference was found in the cause of death between NSBB and non-NSBB group, as well 
as in the incidence of SBP or HRS, although the number of events reported during the follow-
up period was limited. The improved survival we observed in NSBB cohort is in line with the 
increased transplant-free survival reported by Mandorfer et al 12 in cirrhotic patients with 
ascites who were taking NSBBs. However, due to the limited number of SBP episodes, we 
could not evaluate the impact on survival of NSBBs after the occurrence of SBP.  
The benefits of beta-blockers extend over and above primary and secondary prophylaxis of 
variceal bleeding24. Indeed, longitudinal follow up of patients randomised to endoscopic band 
ligation or NSBBs for secondary prophylaxis of variceal bleeding showed increased survival 
in the NSBB group despite a higher rate of re-bleeding, demonstrating an additive therapeutic 
benefits of NSBBs25. This could be due to reduction of bacterial translocation and subsequent 
infection14.  
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The paper by Serste and colleagues has introduced the “window” hypothesis in relation to the 
use of NSBBs in patients with cirrhosis. According to this hypothesis, refractory ascites 
should be an indication for discontinuing NSBBs. We believe that this data adds to the 
substantial evidence published since the Serste paper that argue against this hypothesis. 
Although the use of NSBBs should be cautious in these patients, we should not deprive them 
of their potential beneficial effects. Systolic blood pressure, serum sodium and renal function 
should be evaluated in patients in every outpatient visit or hospitalization, particularly in the 
presence of SBP, in accordance with the recent Baveno guidelines1 and consideration given 
to dose reduction. Until further prospective data are available, a thorough evaluation should 
be carried out before discontinuing these drugs in advanced cirrhosis and such decisions 
should be revisited. 
Our study has limitations that need to be taken into account. Firstly, we could not assess how 
many patients had already been taken off NSBBs at the entry of the study, since we started 
collecting data from the date of liver transplant suitability assessment. Secondly, the relative 
short follow-up due to transplantation might have affected our findings preventing the 
occurrence of detrimental events in patients with more advanced liver disease. Therefore, we 
acknowledge that the applicability of our results to patients not listed for liver transplantation 
should be further explored. Although patients included in this study were followed up when 
the first studies suggesting deleterious effects of NSBBs were published, the departmental 
policy regarding their use did not change. 15 
Although retrospective, our cohort included consecutive well-characterized patients with 
detailed baseline information such as the presence of varices that were lacking in similar 
studies 17 and thorough follow-up. We showed that the use of NSBBs does not harm and 
might actually benefit patients with cirrhosis and ascites. We could not assess the impact of 
NSBBs on survival after an episode of SBP due to the limited number of cases. The lack of 
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significant association between NSBBs and survival observed in the propensity-score 
matched patients could be due to a type II error due to the reduced number of patients 
included in that analysis.  
In conclusion, our data suggest that NSBB use is safe and potentially beneficial in patients 
with cirrhosis and ascites in the liver transplant waiting list. As such patients have a very 
narrow window of opportunity to be transplanted, discontinuation of NSBBs should only 
occur in the events of hypotension, hyponatremia or acute kidney injury.  
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Table 1. Baseline patients’ characteristics  
 All (n=316) 
NSBB  
(n=128) 
No-NSBB 
(n=188) 
P value 
Gender, male 229 (72.5) 94 (73.4) 135 (71.8) 0.75 
Age, years 54 ±10 53.8±10 54.3±10 0.65 
Aetiology of cirrhosis    0.005 
Alcoholic 134 (42) 48 (37) 86 (46)  
Viral hepatitis 82 (26) 44 (34) 38 (20)  
Non-alcoholic 
steatohepatitis 
30 (10) 12   (9) 18 (10)  
Other 70 (22) 24 (19) 46 (24)  
Hepatocellular carcinoma 39 (12) 18 (14) 21 (11) 0.443 
Varices 
small 
medium 
large 
previous endoscopic band 
ligation 
236 (75) 
101 (32) 
13 (4) 
2 (1) 
121 (38) 
126 (98) 
51 (40) 
5 (4) 
2 (1) 
68 (53) 
110 (58) 
49 (26) 
8 (4) 
0 (0) 
53 (28) 
<0.001 
 
 
 
 
Hepatic encephalopathy 98 (31) 46 (36) 52 (28) 0.118 
Severity of ascites    0.013 
Mild 74 (23.4) 40 (31.2) 34 (18.1)  
Moderate 112 (35.4) 45 (35.2) 67 (35.6)  
Severe 130 (41.1) 43 (33.6) 87 (46.3)  
Refractory ascites 124 (39) 41 (32) 83 (44) 0.03 
TIPSS 23 (7.3) 3 (2.3) 20 (11) 0.005 
Diabetes 91 (28.8) 44 (34.4) 47 (25.8) 0.094 
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Malnutrition 156 (49.4) 57 (50.4) 99 (60.4) 0.102 
Mild 7 (2.2) 5 (4.5) 2 (1.2)  
Moderate 93 (29.4) 36 (32.1) 57 (35.6)  
Severe 51 (16.1) 15 (13.4) 36 (22.5)  
Previous variceal bleeding 102 (32.3) 64 (50) 38 (20.7) <0.001 
Previous spontaneous 
bacterial peritonitis 
64 (20.3) 34 (27.4) 30 (16.8) 0.025 
Previous hepatic 
encephalopathy 
143 (45.3) 61 (48) 82 (44.8) 0.576 
Previous hepato-renal 
syndrome 
11 (3.5) 2 (1.6) 9 (4.4) 0.118 
Body mass index, kg/m2 27±6 27±6 27±7 0.992 
Heart rate, bpm 79 (17) 70 (18) 81 (15) <0.001 
Systolic arterial pressure, 
mmHg 
114 (20) 110 (17) 115 (19) 0.073 
Diastolic arterial pressure, 
mmHg 
67 (15) 64 (12) 70 (15) 0.014 
Mean arterial pressure, 
mmHg 
83 (15) 80 (15) 86 (14) 0.012 
Child-Pugh class    0.016 
A 18 (6) 12 (9.4) 6 (3.2)  
B 177 (56) 76 (59.3) 101 (53.7)  
C 121 (38) 40 (31.2) 81 (43.1)  
MELD score 15 (7) 14 (6) 15 (8) 0.125 
UKELD score 55 (7) 54 (6) 55 (7) 0.156 
Platelet count (x109/L) 93 (62) 87 (53) 96 (65) 0.016 
White blood cell count 5.3 (3.2) 5 (3.1) 5.8 (3.3) 0.037 
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(x109/L) 
Haemoglobin (g/dl) 10.9 (2.9) 11.1 (3) 10.7 (3) 0.034 
Bilirubin (mg/dl) 2.34 (2.8) 1.99 (2.11) 2.48 (3) 0.133 
Albumin (g/dl) 3.1 (0.7) 3.2 (0.8) 3.1 (0.8) 0.06 
INR 1.4 (0.5) 1.3 (0.4) 1.4 (0.5) 0.053 
Creatinine (mg/dl) 0.93 (0.38) 0.97 (0.36) 0.91 (0.41) 0.414 
eGFR (ml/min), MDRD 82 (45) 81.5 (42) 84 (49) 0.48 
Sodium (mmol/L) 136 (7) 137 (6) 135 (7) 0.002 
Prophylactic antibiotic 57 (19) 26 (20.3) 31 (17.4) 0.521 
Diuretic treatment     
Furosemide 
- dosage 
114 (36%) 
40 (0) 
60 (47) 
40 (0) 
54 (29) 
40 (5) 
0.002 
Spironolactone 
- dosage 
215 (69) 
100 (100) 
105 (82) 
100 (100) 
110 (60) 
100 (100) 
<0.001 
Values are expressed as number (per cent), mean ±standard deviation and median (interquartile range) 
when appropriate. 
TIPSS, Transjugular intrahepatic portosystemic shunt; NSBB, non-selective beta blocker; MELD, 
Model for End-stage Liver Disease; UKELD, UK score for Patients with End-Stage Liver Disease; 
INR, international normalized ratio; eGFR, estimated glomerular filtration rate; MDRD, modification 
of Diet in Renal Disease;  
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Table 2. Competing risk Cox regression analysis of variables associated with mortality in all patients. 
 Univariate  Multivariate 
HR 95% CI P HR 95% CI P 
Gender, female 1.11 0.68-1.79 0.687    
Age, years 1.03 1.00-1.06 0.097    
Aetiology of cirrhosis 1.02 0.83-1.26 0.850    
Hepatocellular carcinoma 0.70 0.33-1.49 0.352    
Varices  1.17 0.61-2.23 0.633    
Hepatic encephalopathy 1.52 0.95-2.42 0.077    
Severity of ascites       
  Moderate vs mild 1.34 0.72-2.49 0.356    
Severe vs mild 1.56 0.85-2.86 0.155    
Refractory ascites 1.31 0.83-2.08 0.247    
TIPSS  1.52 0.75-3.05 0.242    
Diabetes 0.97 0.57-1.62 0.859    
Malnutrition 1.21 0.73-2.04 0.455    
Severe  2.26 1.30-3.92 0.004    
Previous variceal bleeding 0.90 0.55-1.47 0.670    
Previous spontaneous 
bacterial peritonitis 
0.70 0.37-1.34 0.283    
Previous hepatic 
encephalopathy 
1.13 0.71-1.78 0.612    
Previous hepato-renal 
syndrome 
0.76 0.19-3.00 0.696    
Body mass index 1.00 0.96-1.05 0.901    
Heart rate, bpm 1.02 1.00-1.04 0.074    
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Systolic arterial pressure, 
mmHg 
0.97 0.97-1.00 0.115    
Diastolic arterial pressure, 
mmHg 
0.98 0.95-1.01 0.125    
Mean arterial pressure, mmHg 
0.98 0.95-1.00 0.070    
Child-Pugh score 1.28 1.12-1.46 <0.001    
MELD score 1.09 1.06-1.13 <0.001 1.10 1.06-1.14 <0.001 
UKELD score 1.11 1.08-1.14 <0.001    
Platelet count (x109/L) 1.00 0.99-1.00 0.654    
White blood cell count 
(x109/L) 
1.03 0.96-1.11 0.444    
Haemoglobin (x109/L) 0.86 0.78-1.00 0.050   NS 
Bilirubin (mg/dl) 1.07 1.05-1.09 <0.001    
Albumin (g/dl) 0.96 0.92-1.01 0.083    
INR 1.82 1.23-2.68 0.003    
Creatinine (mg/dl) 1.02 0.69-1.52 0.902    
eGFR (ml/min), MDRD 1.00 0.99-1.00 0.565    
Sodium (mmol/L) 0.93 0.89-0.97 0.001 0.94 0.89-0.98 0.004 
Prophylactic antibiotics 0.45 0.21-1.00 0.049 0.33 0.14-0.74 0.007 
Diuretic treatment       
Furosemide  0.65 0.39-1.06 0.083    
Spironolactone  0.48 0.30-0.77 0.002    
NSBB use 0.48 0.29-0.79 0.004 0.55 0.33-0.94 0.030 
 
TIPSS, Transjugular intrahepatic portosystemic shunt; MELD, Model for End-stage Liver Disease; 
UKELD, UK score for Patients with End-Stage Liver Disease; INR, international normalized ratio; 
eGFR, estimated glomerular filtration rate; MDRD, modification of Diet in Renal Disease; NSBB, 
non-selective beta blocker. 
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Table 3. Competing risk Cox regression analysis of variables associated with mortality in 212 
propensity risk score matched patients with ascites 
 Univariate Multivariate 
 HR 95% CI P HR 95% CI P 
Gender, female 1.29 0.70-2.36 0.414    
Age, years 1.03 0.99-1.07 0.204    
Aetiology of cirrhosis 0.96 0.73-1.27 0.769    
Hepatocellular carcinoma 0.43 0.14-1.38 0.158    
Varices  0.99 0.45-2.15 0.974    
Hepatic encephalopathy 1.70 0.95-3.04 0.072    
Severity of ascites       
  Moderate vs mild 1.17 0.54-2.53 0.697    
Severe vs mild 1.65 0.79-3.48 0.184    
Refractory ascites 1.45 0.80-2.66 0.223    
TIPSS 1.81 0.80-4.09 0.155    
Diabetes 0.83 0.42-1.64 0.575    
Malnutrition 1.55 0.78-3.09 0.216    
Severe  3.45 1.73-6.87 <0.001 2.84 1.45-5.54 0.002 
Previous variceal bleeding 1.19 0.66-2.14 0.570    
Previous spontaneous 
bacterial peritonitis 
0.89 0.40-2.00 0.775    
Previous hepatic 
encephalopathy 
1.54 0.86-2.76 0.143    
Body mass index 0.97 0.92-1.02 0.263    
Heart rate, bpm 1.01 0.99-1.04 0.198    
Systolic arterial pressure, 0.99 0.97-1.01 0.336    
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mmHg 
Diastolic arterial pressure, 
mmHg  
0.99 0.97-1.02 0.705    
Mean arterial pressure, 
mmHg  
0.99 0.96-1.02 0.499    
Child-Pugh score 1.22 1.04-1.42 0.013    
MELD score 1.09 1.04-1.14 <0.001 1.08 1.04-1.12 <0.001 
UKELD score 1.11 1.08-1.14 <0.001    
Platelet count (x109/L) 1.00 0.99-1.00 0.200    
White blood cell count 
(x109/L) 
1.00 0.90-1.11 0.955    
Haemoglobin (g/dl) 0.89 0.77-1.03 0.110    
Bilirubin (mg/dl) 1.06 1.02-1.09 0.002    
Albumin (g/dl) 0.98 0.92-1.04 0.418    
INR 1.65 1.06-2.57 0.026    
Creatinine (mg/dl) 1.44 0.83-2.51 0.197    
eGFR (ml/min), MDRD 0.99 0.98-1.00 0.260    
Sodium (mmol/L) 0.92 0.86-0.97 0.005 0.92 0.86-0.99 0.021 
Prophylactic antibiotics 0.78 0.26-2.17 0.605    
Diuretic treatment       
Furosemide  0.58 0.31-1.10 0.095    
Spironolactone  0.57 0.31-1.06 0.075    
NSBB use 0.62 0.34-1.12 0.114    
TIPSS, transjugular intrahepatic portosystemic shunt; MELD, Model for End-stage Liver Disease; 
UKELD, UK score for Patients with End-Stage LIver Disease;  INR, international normalized ratio;  
eGFR, estimated glomerular filtration rate; MDRD, modification of Diet in Renal Disease; NSBB, 
non-selective beta blocker. 
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Table 4. Competing risk Cox regression analysis of variables associated with mortality in patients 
with refractory ascites 
 Univariate Multivariate 
 HR 95% CI P HR 95% CI P 
Gender, female 0.97 0.42-2.22 0.939    
Age, years 1.02 0.97-1.06 0.472    
Aetiology of cirrhosis 1.35 0.99-1.82 0.055    
Hepatocellular carcinoma 1.13 0.37-3.51 0.829    
Varices 1.05 0.34-3.20 0.933    
Hepatic encephalopathy 1.61 0.80-3.27 0.184    
TIPSS at baseline 1.69 0.71-4.02 0.234    
Diabetes 1.22 0.58-2.56 0.592    
Malnutrition  
- severe 
0.92 
 
2.85 
0.41-2.07 
 
1.37-5.97 
0.844 
 
0.005 
   
Previous variceal bleeding 0.85 0.39-1.83 0.671    
Previous spontaneous bacterial 
peritonitis 
0.72 0.32-1.64 0.436    
Previous hepatic encephalopathy 1.54 0.76-3.13 0.234    
Previous hepato-renal syndrome 0.77 0.20-2.95 0.702    
Body mass index 0.99 0.93-1.06 0.799    
Heart rate, bpm 1.03 0.99-1.06 0.114    
Systolic arterial  pressure, mmHg 0.99 0.97-1.01 0.206    
Diastolic arterial pressure, mmHg 0.97 0.93-1.01 0.092    
Mean arterial pressure, mmHg  0.97 0.94-1.00 0.091    
Child-Pugh score 1.19 0.99-1.44 0.066    
MELD score 1.12 1.08-1.16 <0.001 1.12 1.08-1.16 <0.001 
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UKELD score 1.12 1.08-1.16 <0.001    
Platelet count (x109/L) 1.00 0.99-1.01 0.844    
White blood cell count (x109/L) 1.06 0.95-1.19 0.282    
Haemoglobin (x109/L) 0.96 0.77-1.19 0.701    
Bilirubin (mg/dl) 1.08 1.06-1.10 <0.001    
Albumin (g/dl) 1.01 0.94-1.08 0.828    
INR 3.40 1.80-6.41 <0.001    
Creatinine (mg/dl) 1.09 0.72-1.65 0.684    
eGFR(ml/min), MDRD 1.00 0.99-1.01 0.496    
Sodium (mmol/L) 0.93 0.88-0.99 0.022   NS 
Prophylactic antibiotics 0.58 0.23-1.44 0.242    
Diuretic treatment       
furosemide   0.45 0.20-1.02 0.057    
spironolactone 0.30 0.13-0.72 0.006 0.43 0.20-1.11 0.053 
NSBB use 0.48 0.20-1.14 0.097 0.47 0.20-1.11 0.086 
 
TIPSS, Transjugular intrahepatic portosystemic shunt; MELD, Model for End-stage Liver Disease; 
UKELD, UK score for Patients with End-Stage Liver Disease; INR, international normalized ratio;  
eGFR, estimated glomerular filtration rate; MDRD, modification of Diet in Renal Disease; NSBB, 
non-selective beta blocker; 
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Table 5. Competing risk Cox regression analysis of variables associated with mortality in 58 
propensity risk score matched patients with refractory ascites. 
 Univariate Multivariate 
 HR 95% CI P HR 95% CI P 
Gender, female 1.42 0.51-3.97 0.507    
Age, years 1.01 0.97-1.06 0.561    
Aetiology of cirrhosis 1.08 0.70-1.73 0.763    
Hepatocellular carcinoma 0.60 0.08-4.25 0.610    
Varices  0.60 0.11-3.27 0.559    
Hepatic encephalopathy 1.04 0.39-2.80 0.933    
TIPSS 2.15 0.64-7.28 0.218    
Diabetes 1.39 0.53-3.62 0.499    
Malnutrition 1.21 0.43-3.39 0.715    
Severe  2.84 1.11-7.27 0.030 3.91 1.08-14.20 0.038 
Previous variceal bleeding 0.65 0.24-1.74 0.393    
Previous spontaneous bacterial 
peritonitis 
0.84 0.28-2.49 0.752    
Previous hepatic 
encephalopathy 
2.84 1.00-8.08 0.050   NS
Body mass index 1.01 0.92-1.11 0.844    
Heart rate, bpm 1.04 0.99-1.09 0.066   NS
Arterial systolic pressure, 
mmHg 
0.99 0.97-1.02 0.526    
Arterial diastolic pressure, 
mmHg  
1.01 0.96-1.05 0.805    
Arterial mean pressure, mmHg  1.00 0.96-1.03 0.884    
Child-Pugh score 1.18 0.90-1.55 0.241    
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MELD score 1.16 1.08-1.24 <0.001 1.18 1.10-1.27 <0.001 
UKELD score 1.16 1.07-1.25 <0.001    
Platelet count (x109/L) 1.00 0.98-1.00 0.224    
White blood cell count 
(x109/L) 
1.10 0.86-1.39 0.456    
Haemoglobin (x109/L) 0.71 0.50-1.01 0.056   NS
Bilirubin (mg/dl) 1.06 1.03-1.10 <0.001    
Albumin (g/dl) 1.06 0.99-1.14 0.071   NS
INR 18.00 4.41-73.41 <0.001    
Creatinine (mg/dl) 2.29 1.01-5.19 0.046    
eGFR (ml/min), MDRD 0.98 0.97-1.00 0.024   NS
Sodium 0.95 0.87-1.04 0.261    
Prophylactic antibiotics 0.20 0.02-1.61 0.137    
Diuretic treatment       
Furosemide  0.48 0.17-1.33 0.156    
Spironolactone  0.37 0.12-1.10 0.074   NS
NSBB use 0.34 0.11-1.03 0.057 0.09 0.01-0.54 0.009 
 
TIPSS, Transjugular intrahepatic portosystemic shunt; MELD, Model for End-stage Liver Disease; 
UKELD, UK score for Patients with End-Stage Liver Disease; INR, international normalized ratio; 
eGFR, estimated glomerular filtration rate; MDRD, modification of Diet in Renal Disease; NSBB, 
non-selective beta blocker 
